Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Galapagos

DB:GXE
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GXE
DB
€11B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
  • Galapagos has significant price volatility in the past 3 months.
GXE Share Price and Events
7 Day Returns
8.1%
DB:GXE
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
58.1%
DB:GXE
-13.2%
DE Biotechs
-20.9%
DE Market
GXE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Galapagos (GXE) 8.1% -3.6% -4.4% 58.1% 111.7% 676.8%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • GXE outperformed the Biotechs industry which returned -13.2% over the past year.
  • GXE outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
GXE
Industry
5yr Volatility vs Market
Related Companies

GXE Value

 Is Galapagos undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Galapagos to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Galapagos.

DB:GXE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 17 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:GXE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.2%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 29%) (0.22%))
1.127
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.127 * 6.21%)
6.61%

Discounted Cash Flow Calculation for DB:GXE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Galapagos is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:GXE DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.61%)
2020 -531.07 Analyst x3 -498.14
2021 -441.31 Analyst x4 -388.28
2022 -240.57 Analyst x3 -198.54
2023 83.53 Analyst x2 64.66
2024 671.92 Analyst x2 487.91
2025 1,150.71 Est @ 71.26% 783.76
2026 1,723.32 Est @ 49.76% 1,101.01
2027 2,321.59 Est @ 34.72% 1,391.28
2028 2,883.05 Est @ 24.18% 1,620.63
2029 3,367.75 Est @ 16.81% 1,775.72
Present value of next 10 years cash flows €6,140.00
DB:GXE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €3,367.75 × (1 + -0.39%) ÷ (6.61% – -0.39%)
€47,925.47
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €47,925.47 ÷ (1 + 6.61%)10
€25,269.75
DB:GXE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €6,140.00 + €25,269.75
€31,409.75
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €31,409.75 / 64.82
€484.58
DB:GXE Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:GXE represents 1.00602x of ENXTAM:GLPG
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.00602x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 484.58 x 1.00602
€487.49
Value per share (EUR) From above. €487.49
Current discount Discount to share price of €175.55
= -1 x (€175.55 - €487.49) / €487.49
64%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Galapagos is available for.
Intrinsic value
>50%
Share price is €175.55 vs Future cash flow value of €487.49
Current Discount Checks
For Galapagos to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Galapagos's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Galapagos's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Galapagos's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Galapagos's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GXE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €2.60
ENXTAM:GLPG Share Price ** ENXTAM (2020-04-03) in EUR €174.5
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Galapagos.

DB:GXE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTAM:GLPG Share Price ÷ EPS (both in EUR)

= 174.5 ÷ 2.60

67.09x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Galapagos is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Galapagos is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Galapagos's expected growth come at a high price?
Raw Data
DB:GXE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 67.09x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts
15.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

DB:GXE PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 67.09x ÷ 15.5%

4.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Galapagos is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Galapagos's assets?
Raw Data
DB:GXE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €44.47
ENXTAM:GLPG Share Price * ENXTAM (2020-04-03) in EUR €174.5
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:GXE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTAM:GLPG Share Price ÷ Book Value per Share (both in EUR)

= 174.5 ÷ 44.47

3.92x

* Primary Listing of Galapagos.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Galapagos is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Galapagos's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Galapagos has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

GXE Future Performance

 How is Galapagos expected to perform in the next 1 to 3 years based on estimates from 17 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Galapagos expected to grow at an attractive rate?
  • Galapagos's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Galapagos's earnings growth is expected to exceed the Germany market average.
  • Galapagos's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:GXE Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GXE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts 15.5%
DB:GXE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 17 Analysts 9.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GXE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GXE Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 1,321 657 296 8
2023-12-31 1,039 53 141 9
2022-12-31 888 -264 -98 13
2021-12-31 634 -401 -193 17
2020-12-31 616 -382 -138 17
2020-04-05
DB:GXE Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 896 3,209 150
2019-09-30 865 3,281 280
2019-06-30 324 -193 -66
2019-03-31 314 -174 -41
2018-12-31 318 -142 -29
2018-09-30 255 -156 -74
2018-06-30 185 -187 -126
2018-03-31 161 -164 -139
2017-12-31 156 -147 -116
2017-09-30 193 -51 -40
2017-06-30 176 -42 -27
2017-03-31 177 -35 4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Galapagos's earnings are expected to grow by 15.5% yearly, however this is not considered high growth (20% yearly).
  • Galapagos's revenue is expected to grow by 9.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GXE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below

All data from Galapagos Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GXE Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.60 -0.60 -0.60 1.00
2023-12-31 5.01 10.02 0.00 2.00
2022-12-31 -0.44 2.60 -3.00 4.00
2021-12-31 -1.51 -0.15 -3.20 5.00
2020-12-31 -0.28 0.52 -0.78 4.00
2020-04-05
DB:GXE Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 2.60
2019-09-30 5.07
2019-06-30 -1.23
2019-03-31 -0.77
2018-12-31 -0.56
2018-09-30 -1.45
2018-06-30 -2.46
2018-03-31 -2.75
2017-12-31 -2.34
2017-09-30 -0.83
2017-06-30 -0.58
2017-03-31 0.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Galapagos is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Galapagos's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Galapagos has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

GXE Past Performance

  How has Galapagos performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Galapagos's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Galapagos has delivered over 20% year on year earnings growth in the past 5 years.
  • Galapagos has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Galapagos has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Galapagos's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Galapagos Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GXE Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 895.89 149.85 98.28
2019-09-30 865.23 280.29 74.14 188.83
2019-06-30 324.48 -66.11 52.11 188.83
2019-03-31 313.93 -40.63 43.63 188.83
2018-12-31 317.85 -29.26 39.78
2018-09-30 254.64 -74.06 34.37 95.84
2018-06-30 184.76 -125.51 30.41 95.84
2018-03-31 160.89 -139.38 28.17 95.84
2017-12-31 155.92 -115.70 27.22
2017-09-30 192.93 -39.91 26.43 67.59
2017-06-30 175.88 -27.47 25.85 67.59
2017-03-31 176.66 4.46 25.29 67.59
2016-12-31 151.61 54.01 23.53 67.59
2016-09-30 78.40 -48.94 23.49 48.88
2016-06-30 72.42 -52.00 21.79 48.88
2016-03-31 55.37 -68.23 20.92 48.88
2015-12-31 60.58 -118.41 20.31 48.88
2015-09-30 74.57 -71.70 17.65 34.81
2015-06-30 81.89 -56.87 16.69 34.81
2015-03-31 87.52 -44.22 14.95 34.81
2014-12-31 90.02 -37.30 14.87 34.81
2014-09-30 86.35 -32.43 14.05 6.41
2014-06-30 92.40 -25.47 13.87 12.81
2014-03-31 94.49 -21.14 13.84 19.70
2013-12-31 96.57 -16.81 13.82 26.60
2013-09-30 55.40 -10.29 4.18 42.70
2013-06-30 137.74 -0.34 21.04 13.79

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Galapagos has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Galapagos used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Galapagos has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Galapagos's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Galapagos has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

GXE Health

 How is Galapagos's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Galapagos's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Galapagos is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Galapagos's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Galapagos's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Galapagos has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Galapagos Company Filings, last reported 3 months ago.

DB:GXE Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 2,875.66 0.00 5,780.83
2019-09-30 2,535.28 0.00 5,599.79
2019-06-30 1,143.37 0.00 1,147.92
2019-03-31 1,175.76 0.00 1,222.90
2018-12-31 1,214.25 0.00 1,290.80
2018-09-30 1,188.22 0.00 1,343.67
2018-06-30 885.66 0.00 1,066.77
2018-03-31 899.35 0.00 1,108.19
2017-12-31 1,011.98 0.00 1,151.21
2017-09-30 1,036.93 0.00 1,218.86
2017-06-30 1,069.03 0.00 1,262.06
2017-03-31 748.15 0.00 953.39
2016-12-31 758.70 0.00 973.24
2016-09-30 708.82 0.00 930.81
2016-06-30 729.80 0.00 960.48
2016-03-31 728.55 0.00 978.33
2015-12-31 365.00 0.00 340.31
2015-09-30 418.79 0.00 366.55
2015-06-30 443.46 0.00 397.48
2015-03-31 206.14 0.17 187.71
2014-12-31 206.14 0.00 187.71
2014-09-30
2014-06-30 224.99 0.00 220.81
2014-03-31 224.99 0.00 220.81
2013-12-31 167.14 0.00 138.18
2013-09-30 167.14 0.00 138.18
2013-06-30 168.01 0.00 136.71
  • Galapagos has no debt.
  • Galapagos had no debt 5 years ago.
  • Galapagos has no debt, it does not need to be covered by operating cash flow.
  • Galapagos has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Galapagos's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Galapagos has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

GXE Dividends

 What is Galapagos's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Galapagos dividends. Estimated to be 0% next year.
If you bought €2,000 of Galapagos shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Galapagos's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Galapagos's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GXE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GXE Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31 0.00 1.00
2022-12-31 0.00 2.00
2021-12-31 0.00 4.00
2020-12-31 0.00 4.00
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Galapagos has not reported any payouts.
  • Unable to verify if Galapagos's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Galapagos's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Galapagos has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Galapagos's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Galapagos's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Galapagos afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Galapagos has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

GXE Management

 What is the CEO of Galapagos's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Onno van de Stolpe
COMPENSATION €1,480,627
AGE 60
TENURE AS CEO 21.3 years
CEO Bio

Mr. Onno van de Stolpe co-founded Galapagos NV in 1999 and has been Chief Executive Officer and Managing Director since 1999. Mr. van de Stolpe served as the Managing Director Genomics at IntroGene BV. He joined IntroGene in 1998. He served as the Managing Director of Molecular Probes Europe bv. He established this European headquarters of Molecular Probes, Inc. in 1995. He joined the Eugene-based organization in the USA in 1994. He worked for the Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotech and medical device companies to locate in the Netherlands. He started his career as a Manager Business Development at MOGEN NV in Leiden. He serves as an Executive Director of Galapagos NV. Mr. van de Stolpe serves as a Member of Supervisory Board at DCPrime B.V. Mr. van de Stolpe received MSc degree from the Agricultural University in Wageningen.

CEO Compensation
  • Onno's compensation has increased in line with Galapagos recently becoming profitable.
  • Onno's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Galapagos management team in years:

6
Average Tenure
55
Average Age
  • The average tenure for the Galapagos management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Onno van de Stolpe

TITLE
Co-Founder
COMPENSATION
€1M
AGE
60
TENURE
21.3 yrs

Bart Filius

TITLE
CFO & COO
AGE
49
TENURE
5.3 yrs

Piet Wigerinck

TITLE
Chief Scientific Officer
AGE
55
TENURE
8.3 yrs

Elizabeth Goodwin

TITLE
Vice President of Investor Relations

Carmen Vroonen

TITLE
Senior Director of Communications & Public Affairs

Andre Hoekema

TITLE
Chief Business Officer
AGE
62
TENURE
2.6 yrs

John Montana

TITLE
Managing Director of Argenta
TENURE
6.7 yrs

Walid Abi-Saab

TITLE
Chief Medical Officer
AGE
54
TENURE
3.1 yrs

Chantal Tasset

TITLE
Head of Development

Ellen Aar

TITLE
Head of Development
Board of Directors Tenure

Average tenure and age of the Galapagos board of directors in years:

5.4
Average Tenure
57
Average Age
  • The tenure for the Galapagos board of directors is about average.
Board of Directors

Raj Parekh

TITLE
Non-Executive Chairman
COMPENSATION
€90K
AGE
59
TENURE
16.3 yrs

Onno van de Stolpe

TITLE
Co-Founder
COMPENSATION
€1M
AGE
60
TENURE
21.3 yrs

Howard Rowe

TITLE
Independent Non-Executive Director
COMPENSATION
€53K
AGE
50
TENURE
9.6 yrs

Katrine Bosley

TITLE
Independent Non-Executive Director
COMPENSATION
€45K
AGE
51
TENURE
7.1 yrs

Mary Kerr

TITLE
Independent Non-Executive Director
COMPENSATION
€44K
AGE
58
TENURE
3.8 yrs

Peter Guenter

TITLE
Director
AGE
57
TENURE
1 yrs

Dan O'Day

TITLE
Non-Independent Director
AGE
55
TENURE
0.5 yrs

Linda Higgins

TITLE
Non-Independent Director
AGE
57
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Galapagos's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Galapagos has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

GXE News

Simply Wall St News

GXE Company Info

Description

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company’s clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, and ulcerative colitis; Phase II trials for small bowel CD, fistulizing CD, Sjögren’s syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. Its clinical stage programs also comprise GLPG1690I, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof of concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, the company engages in the development of GLPG1972, which is in the ROCCELLA Phase II trial in osteoarthritis patients; MOR106 that is in Phase I and II trials in atopic dermatitis patients; and GLPG3312, a Toledo molecule, which is in Phase I clinical development for various indications. Galapagos NV has collaboration agreement with Servier for GLPG1972; Les Laboratoires Servier for GLPG1972; MorphoSys AG and Novartis Pharma AG for MOR106; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis; and Evotec for fibrosis, as well as a drug discovery research collaboration agreement with HitGen to identify small molecule leads. The company was founded in 1999 and is headquartered in Mechelen, Belgium.

Details
Name: Galapagos NV
GXE
Exchange: DB
Founded: 1999
€11,310,919,339
64,819,022
Website: http://www.glpg.com
Address: Galapagos NV
Generaal De Wittelaan L11 A3,
Mechelen,
Antwerp, 2800,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTAM GLPG Ordinary Shares Euronext Amsterdam NL EUR 06. May 2005
OTCPK GLPG.F Ordinary Shares Pink Sheets LLC US USD 06. May 2005
DB GXE Ordinary Shares Deutsche Boerse AG DE EUR 06. May 2005
LSE 0JXZ Ordinary Shares London Stock Exchange GB EUR 06. May 2005
WBAG GLPG Ordinary Shares Wiener Boerse AG AT EUR 06. May 2005
ETLX GXE Ordinary Shares Eurotlx IT EUR 06. May 2005
BATS-CHIXE GLPGA Ordinary Shares BATS 'Chi-X Europe' GB EUR 06. May 2005
NasdaqGS GLPG SPON ADR REPR 1 ORD SHS Nasdaq Global Select US USD 02. May 2008
DB GXEA SPON ADR REPR 1 ORD SHS Deutsche Boerse AG DE EUR 02. May 2008
Number of employees
Current staff
Staff numbers
1,003
Galapagos employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 22:20
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/03/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.